Ivermectin as a SARS-CoV-2 Pre-Exposure Prophylaxis Method in Healthcare Workers: A Propensity Score-Matched Retrospective Cohort Study [Published August 26,2021]

Purpose: Primary outcome was to measure the number of healthcare workers with symptomatic SARS-CoV-2 infection and a positive reverse transcription polymerase chain reaction (RT-PCR) COVID-19 test in the ivermectin group and in the control group. Secondary outcome was to measure the number of sick healthcare workers with a positive RT-PCR COVID-19 test whose condition deteriorated and required hospitalization and/or an Intensive Care Unit (ICU), or who died, in the ivermectin group and in the control group.

Material and methods: This observational and retrospective cohort study was carried out in two medical centers, Centro Medico Bournigal (CMBO) in Puerto Plata and Centro Medico Punta Cana (CMPC) in Punta Cana, Dominican Republic. The study began on June 29, 2020, and ended on July 26, 2020. A Statistical Package for Social Sciences (SPSS) Propensity Score Matching procedure was applied in a 1:1 ratio to homogeneously evaluate 271 healthcare personnel that adhered to a PrEP program with ivermectin at a weekly oral (PO) dose of 0.2 mg/kg, and 271 healthcare personnel who did not adhere to the program were assigned as a control group.

Results: In 28 days of follow-up, significant protection of ivermectin preventing the infection from SARS-CoV-2 was observed: 1.8% compared to those who did not take it (6.6%; p-value = 0.006), with a risk reduction of 74% (HR 0.26, 95% CI [0.10,0.71]).

Conclusions: These results suggest that compassionate use of weekly ivermectin could be an option as a preventive method in healthcare workers and as an adjunct to immunizations,

Results

Initially 943 candidates were selected for the study, from which 43 were excluded for having a positive COVID-19 RT-PCR report before the start of the study. The ivermectin group was made up of 510 healthcare personnel and the control group was made up of 390 participants. In total, 182 healthcare workers who did not comply with the ivermectin doses described in the inclusion criteria were excluded from the ivermectin group. In the follow-up study, five participants were lost who resigned or were dismissed from their work, two in the ivermectin group and three in the control group. This equates to a 0.6% loss of the follow-up for the ivermectin group and 0.77% for the control group. As it is less than 5%, it is not considered relevant for the purposes of the study.

Finally, 713 participants were chosen, 326 in the ivermectin group and 387 in the control group, and were considered for the preliminary analysis of this study. After the matching process with the Propensity Score, there were 271 members in each group for analysis (Figure 1).

51.5% of the participants in the ivermectin group took four doses, 40.4% took three doses, 6.7% took two doses, and 1.4% of the participants managed to take a single dose and then reported a positive COVID-19 infection. The median time between doses was seven days and the mean (average) was 7.2 days with a standard deviation of 1.03.

There were no severe side effects reported from the use of ivermectin, only minor side effects such as dizziness (3.7%), headache (1.5%), stomachache (1.4%), pruritus (1.1%), nausea (1.1%) and diarrhea (0.7%).

Limitations

The study was limited to 28 days, as in August 2020 the prevention scheme changed to a monthly dose of ivermectin 0.4 mg/kg. There was no RT-PCR test at the start or exit of this study, neither in the ivermectin group nor in the control group. There is the possibility that asymptomatic cases were not detected. Additionally, selection of groups was based on adherence.

Conclusions

Pre-exposure prophylaxis (PrEP) for COVID-19 with a weekly oral dose of ivermectin 0.2 mg/kg was statistically significant in exposed healthcare personnel at the CMBO and CMPC after 28 days of follow up, with only 1.8% of the physicians and health collaborators developing SARS-CoV-2 infection versus 6.6% in the control group (p-value = 0.006). Ivermectin reduced the risk of contagion with COVID-19 by 74% compared to the control group (HR 0.26, 95% CI [0.10, 0.71]). These results suggest that compassionate use of weekly ivermectin could be an option as a preventive method in healthcare workers and as an adjunct to immunizations, while further well-designed randomized controlled trials are developed to facilitate scientific consensus.

When comparing both groups the difference was not statistically significant in deterioration that required hospitalization and/or ICU (p-value=0.499) and in death (p-value=1.000

a) not so experimental vaccine at 85-90% against Wuhan original and 70-85% Delta symptom protection and 95%+ overall death protection that’s proven, or
b) an experimental parasitic at 74% effective symptom protection after 16-28 days, if taken religiously forever (although some of those in India still got sick) and no statistical protection against death. Its excretion is 99% hepatic and only 1% is excreted in the urine (got liver?)
c) go naked

Unfortunately, this study only looks at ivermectin challenged by Alpha Covid.

But we’re beyond alpha. These studies would have to be repeated with ivermectin challenged by Delta to get a more accurate percentage of protection real-time.

Heres the scoop on Ivermectin:

If you cannot get a physician’s prescription, you can order it here:

1) https://www.ziverdo-kit.com

2) https://www.indiamart.com ( get 12 mg tabs)

Protocols to follow for both Prophylaxis and Therapy for Infection:

https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-I-MASK-Protocol-v4-2020-11-22.pdf

Ivermectin is no longer a banned treatment by the CDC. They are just “not recommending” it.

You will need over the counter Zinc, Vitamin D and Quercetin supplements.

Hundreds of Feepers stocked up over the last 6 months.

********************************

https://www.researchgate.net/publication/343390023_Ivermectin_docks_to_the_SARS-CoV-2_spike_receptor-binding_domain_attached_to_A

There is reasonably solid evidence that ivermectin docks to the spike protein itself to prevent binding to the ACE2 receptor which is the primary pathology causing the tissue damage and clots related to SARS-CoV-2. Therefore, this is also an implication that this ability of ivermectin to disable the binding of the Spike protein including the vaccine-produced spike proteins. This binding of ivermectin to disable the spike protein is also preserved even with the newer spike protein mutations, but its activity against the original Wuhan spike protein,(the one vaccines were designed to produce) is fairly well studied at this point.

Abstract:

Background/Aim: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. We carried out a docking study to determine if ivermectin might be able to attach to the SARS-CoV-2 spike receptor-binding domain bound with ACE2. Materials and Methods: We used the program AutoDock Vina Extended to perform the docking study. Results: Ivermectin docked in the region of leucine 91 of the spike and histidine 378 of the ACE2 receptor. The binding energy of ivermectin to the spike-ACE2 complex was -18 kcal/mol and binding constant was 5.8 e-08. Conclusion: The ivermectin docking we identified may interfere with the attachment of the spike to the human cell membrane. Clinical trials now underway should determine whether ivermectin is an effective treatment for SARS-Cov2 infection.

The following video explains the multiple mechanisms of the activity of Ivermectin including the ability of the body to maintain its basic defense of the cell nucleus in preserving the body’s ability to produce antiviral proteins, inhibition of RNA dependant RNA polymerase which inhibits the replication of viral RNA (possibly including that from the mRNA vaccine package), the stat 3 human signaling pathway which inhibits the production of blood clots also possibly mitigating some of the vaccines most dangerous side effects. Also discussed is the inhibition of the CD147 pathway by ivermectin which again may block the clumping of platelets due to spike protein either from the virus or possibly the vaccines.

Note: Ivermectin therapy likley will gradually rid the body of spike proteins altogether, something to remember for those who might have residual side effects from mRNA vaccine.

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.